A B S T R A C T The biochemical mechanisms by which a genetically determined deficiency of adenosine deaminase leads to immunodeficiency are still poorly understood and prompted this study. We have examined the effects of the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA) upon the response of human peripheral blood mononuclear cells to the mitogen concanavalin A (Con A). Cells isolated from normal volunteers were incubated in microtiter plates in the presence of various inhibitors, and the incorporation of tritrated thymidine or leucine into macromolecular material was measured after 64 h.
EHNA at a concentration of 0.3 /LM, which inhibited 90% of the adenosine deaminase (ADA) activity in a mononuclear preparation, impaired the incorporation of tritrated leucine into protein; 100 /M EHNA was the minimal concentration that inhibited thymidine uptake. The addition of 15 ,M adenosine or 10 ,M cyclic AMP to Con A-stimulated lymphocytes inhibited leucine uptake, while millimolar concentrations were required to inhibit thymidine uptake. Lower doses of adenosine and cyclic AMP stimulated thymidine incorporation. The inhibition of thymidine uptake observed with millimolar concentrations of adenosine was independent of the type of mitogen (pokeweed or Con A), the concentration of mitogen, or the medium used, but could be increased if the cells were cultured in a serum with reduced levels of adenosine deaminase. Washout experiments failed to demonstrate a critical period early in immune induction during which adenosine exerted its inhibitory effects. Noninhibitory doses of EHNA potentiated the effects of adenosine and cyclic AMP on leucine and thymidine uptake. EHNA at a concentration of 50 /AM also Dr. Carson is a postdoctoral fellow of the Arthritis Foundation.
INTRODUCTION
Recently, several children with combined immunodeficiency disease have been found who lack the enzyme adenosine deaminase (1) (2) (3) (4) . Since both disorders are extremely rare, their concurrent appearance in at least 14 different families provides a convincing argument for a causal relationship of the enzyme defect to the appearance of the clinical disease. Several recent experiments have attempted to elucidate the function of adenosine deaminase during lymphocyte growth and differentiation.
The addition of exogenous adenosine, and in some cases of adenine nucleotides, has been shown to inhibit the phytohemagglutinin-induced blastogenesis of normal human lymphocytes (5, 6) , the growth of human lymphoblast cell lines (7) , and the in vitro destruction of human cells by specifically sensitized mouse lymphocytes (8) . In the latter case, Wolberg and co-workers demonstrated that the sensitivity of lymphocytes to adenosine could be potentiated by the presence of an inhibitor of adenosine deaminase, erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA)1 (9) .
'Abbreziations used in this paper: Con A, concanavalin A; EHNA, erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride.
Whether or not the immunodeficiency associated with adenosine deaminase deficiency is due to adenosine toxicity is at present unknown, since adenosine levels have not been measured in affected patients. Adenosine in high concentrations, however, can block the formation of phosphoribosyl pyrophosphate, necessary for de novo purine and pyrimidine biosynthesis,' and in some systems can also elevate intracellular cyclic AMP levels (10, 11) . These consequences of adenosine accumulation would be expected to interfere with lymphocyte proliferation, but the relative importance of each, if any, is unknown.
In this report we examine the effects of the adenosine deaminase inhibitor EHNA upon human peripheral lymphocyte mitogenesis, and its ability to potentiate the effects of adenosine and cyclic AMP. The results indicate that inhibition of adenosine deaminase alone can significantly impair lymphocyte transformation, as well as sensitize the lymphocytes to the inhibitory effects of exogenous adenosine. The recent report of nucleoside phosphorylase deficiency in a patient with T-cell immunodeficiency (12) provides additional support for the view that metabolism of purine bases and nucleosides is critically important for the normal function of the immune system.
METHODS
Lymphocyte isolation. Blood from healthy laboratory volunteers was collected with heparin (The Upjohn Company, Kalamazoo, Mich.) as anticoagulant, and the erythrocytes were sedimented for 1 h at 37'C in the presence of 0.6% vol/vol Macrodex dextran (Pharmacia Fine Chemicals, Piscataway, N. J.). 5-ml portions of the leukocyte-rich plasma were layered over 2 ml Ficoll-Hypaque (obtained as LSM solution from Litton Bionetics, Kensington, Md.) and centrifuged at 1,800 g for 10 min in 16 X 100-cm plastic tubes (Falcon 3030, Falcon Plastics, Div. of BioQuest, Oxnard, Calif.). The lymphocyte-containing interphase was recovered, washed twice in RPMI 1640 medium (Flow Laboratories, Inc., Rockville, Md.), and counted in a hemocytometer. Cell yield averaged 106/ml of blood. When examined by light microscopy after Wright's staining, 95% of the cells were mononuclear with variable platelet contamination.
Culture conditions. Lymphocytes were cultured in microplates (Falcon 3040) containing 2 X 10' cells in a final volume of 0.22 ml. Unless otherwise indicated, all cultures contained 10% AB, Rh-positive human serum, obtained from pooled, outdated blood plasma, and either RPMI 1640 or Eagle's minimal essential medium supplemented with penicillin (100 gg/ml), streptomycin (100 U/ml), and glutamine (2 mM). Unless otherwise indicated, the serum was heated for 1 h at 56'C before use, to denature adenosine deaminase partially. Mitogens were added at just below optimal concentrations, i.e., 25 sg/ml for concanavalin A (Con A) (Sigma Chemical Co., Inc., St. Louis, Mo.) and 5 ,ul/ml for pokeweed mitogen (Grand Island Biological Co., Grand Island, N. Y., prepared from a stock solution 'Snyder, F., and J. E. Seegmiller. Manuscript in preparation. diluted in medium as described by the manufacturers). In those experiments where lymphocytes were cultured in the absence of serum, Con A was used at a concentration of 1.5 Ag/ml. The plates were incubated in a humidified atmosphere containing 5%o carbon dioxide and 95% air. Unless otherwise stated, Con A was the mitogen used in all experiments.
In some cases, where indicated, lymphocytes were cultured in 12 X 75-mm plastic tubes (Falcon 2058) in a volume of 1 ml. After varying periods, they were centrifuged at 80 g for 5 min and resuspended in fresh medium. Conditions were otherwise identical to those described above.
Measurement Statistical analysis. The absolute amount of radioactivity incorporated by mitogen-stimulated lymphocytes varied from day to day and among different subjects. To normalize the data, all cultures containing inhibitors of transformation were always compared with control cultures lacking inhibitors and processed on the same day. Results are expressed as percent control counts= (counts incorporated in the presence of inhibitor/counts incorporated in the absence of inhibitor) X 100. The results of multiple repetitive cultures on several different individuals were used to calculate a mean percent control counts±SEM. Where applicable, the means of the drug-treated groups were compared, and the null hypothesis was accepted or rejected by the Mann-Whitney U test (14) . Two drugs were considered to have a synergistic effect when the inhibition produced by the drugs together was greater than the sum of the inhibitions when each drug was used separately.
Miscellaneous. EHNA was a gift of Dr. Howard Schaeffer. Adenosine, uridine, cytidine, orotic acid, butyric acid, norepinephrine, isoproterenol, and theophylline were purchased from Sigma and used without further purification. Adenosine 3',5'-cyclic phosphate (cyclic AMP) and NO2-dibutyryl adenosine cyclic phosphate (dibutyryl cyclic AMP) were purchased as their sodium salts from P-L Biochemicals (Milwaukee, Wis.). All reagents were dissolved in RPMI 1640 and sterilized by ultrafiltration before use.
RESULTS
Effects of exogenous adenosine. Adenosine added at the time of initiation of lymphocyte cultures did not impair the subsequent incorporation of [6- 'H] thymidine until millimolar concentrations were reached ( Fig. 1) .
At lower doses (10-100 sM), exogenous adenosine had a slight but significant (P <0.005) stimulatory effect on thymidine uptake.
The characteristic dose-response curve observed with the addition of exogenous adenosine was independent of the type of mitogen (pokeweed or Con A), the concentration of mitogen, or the medium used (RPMI 1640 or Eagle's minimal essential medium). Diminishing or removing adenosine deaminase from the medium did, however, increase the toxicity of adenosine. By heating the human serum in which the cells were cultured to 560C for 1 h, which partially denatures adenosine deaminase (15) , or by using horse serum, which lacks detectable enzyme, the inhibition of thymidine uptake seen with millimolar concentrations of adenosine was increased from 56% to 78% (P < 0.005).
The dose-response curve seen with varying concentrations of adenosine did not differ significantly when a 4-h rather than a 16-h pulse of tritiated thymidine was used.
As shown in Table I , concentrations of adenosine as low as 15 AM significantly inhibited the incorporation of tritiated leucine into protein (P < 0.005). Lower concentrations of adenosine did not stimulate leucine uptake.
Effects of EHNA. The adenosine deaminase inhibitor EHNA did not inhibit thymidine uptake until a concentration of 100 AM was reached (Table II) . At a concentration of 10 AM, EHNA, like adenosine, increased thymidine uptake, although at the same concentration, 61±4 23±3 n = 9 n = 9 n = 9 n = 9 n = 9 ND n = 9 n = 9 n = 9 5.0 adenosine deaminase activity in lymphocyte extracts could be 99% inhibited (Fig. 2) . On the other hand, when leucine incorporation into protein was measured, EHNA concentrations as low as 0.3 AM had a significant inhibitory effect (P <0.01), at which concentration the adenosine deaminase activity in lymphocyte extracts was 90% inhibited.
Potentiation of adenosine inhibition by EHNA. In the presence of 50 cM EHNA, adenosine at concentrations as low as 10 ,M inhibited thymidine uptake (Ta- Results are expressed as the mean percent control counts ±SEM for the indicated number of cultures.
ble II
). An EHNA concentration of 0.1 EM or greater was effective in potentiating the inhibitory effects of adenosine on protein synthesis (P < 0.05) ( Table I) .
Effect of uridine. The presence of uridine in the medium at a concentration of 10 gM substantially diminished but did not completely reverse the inhibitory effects of adenosine on thymidine and leucine uptake (Fig. 3) . At after the addition of mitogen. As expected, the later the adenosine was added, the less it inhibited the subsequent uptake of tritiated thymidine (Fig. 4) . Similarly, when
Con A-stimulated lymphocytes were cultured in the presence of 50 MM EHNA and 50 MM adenosine and the inhibitors were washed out at varying time periods, diminished inhibition was observed. There was no apparent critical period early in immune induction during which adenosine exerted its inhibitory effects. Rather, the percent inhibition observed when adenosine and EHNA were incubated with lymphocytes was proportional to the length of time the agents were in contact with the cells, whether this occurred early or late after the addition of mitogen. Effect of exogenous cyclic AMP and dibutyryl cyclic AMP. The addition of exogenous cyclic AMP to lymphocyte cultures did not inhibit thymidine uptake until millimolar concentrations were reached (Table III) . At a cyclic AMP concentration of 100 AM, thymidine uptake was increased 16% over control values (P < 0.005). Cyclic AMP concentrations as low as 10 MM inhibited the incorporation of tritiated leucine into protein (P <0.01) ( Table I) .
Dibutyryl cyclic AMP, on a molar basis, was more than 10 times as potent as cyclic AMP as an inhibitor of thymidine uptake (Table III) . In addition it did not stimulate thymidine uptake at concentrations as low as 0.001 MM. In control experiments, at least part of the effect of dibutyryl cyclic AMP could be attributed to its breakdown product butyric acid, particularly at concentrations greater than 100 FM. Monobutyryl cyclic AMP, however, was just as effective an inhibitor as dibutyryl cyclic AMP (results not shown), although only one half as much butyric acid could be generated.
The presence of 10 MM uridine in the medium was able to protect the lymphocytes from the inhibitory effects of exogenous cyclic AMP. On the other hand, uridine had no effect on the toxicity of dibutyryl cyclic AMP.
The adenosine deaminase inhibitor EHNA at a concentration of 50 MM potentiated the inhibitory effects of cyclic AMP and, to a lesser degree, dibutyryl cyclic AMP on thymidine uptake (Table III) . Thus, at a concentration of 1 mM cyclic AMP, tritiated thymidine uptake was 85±4% of control values; the addition of 50 MM EHNA lowered this to 25±5% (P < 0.005). The addition of EHNA to cultures containing 10 FM dibutyryl cyclic AMP lowered tritiated thymidine uptake from 65+2 to 42+3% of controls (P < 0.005). In other experiments (results not shown), EHNA was unable to potentiate the inhibitory effects of dibutyryl cyclic AMP upon leucine incorporation into protein.
Effect of pharmacologic agents. Because of difficulties in ascertaining how much of the effects of dibutyryl cyclic AMP were actually due to butyric acid, we also tested the effects of EHNA and uridine in modifying the inhibition of thymidine uptake caused by norepinephrine, isoproterenol, and theophylline (Table IV) . EHNA at a concentration of 50 MM significantly enhanced the toxicity observed at 30 and 100 FM concentrations of norepinephrine (P < 0.005). The effect of EHNA on isoproterenol was marginal until 100 WM concentrations of the latter compound were reached, at which point significant enhancement was observed (P < 0.05). EHNA had no effect on the inhibition of thymidine uptake caused by theophylline at concentrations as high as 1 mM.
In other experiments (results not shown) adenosine alone at concentrations up to 100 MM did not potentiate norepinephrine toxicity. EHNA had no effect upon the inhibition of leucine uptake induced by norepinephrine, isoproterenol, or theophylline. Uridine was unable to re- 36±5 NS * The mean percent control counts and the significance values were determined as described in Table III . The results of triplicate cultures are expressed as: mean percent maximal inhibition = 100 X (1 -radioactivity incorporated when cells were exposed to inhibitors for a limited time/radioactivity incorporated when cells were exposed continuously to inhibitors.).
verse the inhibition of thymidine or leucine uptake caused by norepinephrine, isoproterenol, or theophylline.
DISCUSSION
In the experiments reported here, we have examined in detail the effect of inhibition of adenosine deaminase upon the response of normal peripheral blood lymphocytes to mitogens. The addition of the adenosine deaminase inhibitor EHNA at concentrations as low as 0.3 ,iM to Con A-stimulated lymphocytes impaired the subsequent incorporation of tritiated leucine into protein.
At this concentration of EHNA, the adenosine deaminase activity of a lymphocyte extract was inhibited 90%. In our laboratory, concentrations of EHNA at least 10 times higher are necessary to inhibit the growth of longterm human lymphocyte and fibroblast lines. Thus the normal human peripheral blood lymphocyte undergoing blastogenesis is a cell particularly susceptible to the effects of adenosine deaminase inhibition.
Thymidine uptake was a far less sensitive index of EHNA toxicity than leucine uptake, probably due to an adenosine-like effect of EHNA. Hilz and Kaukel have shown in isolated HeLa cells that adenosine, by depleting pyrimidine nucleotide pools, could proportionally increase the specific activity of added tritiated thymidine or uridine (16, 17) . This led to the paradoxical effect of an increase in thymidine incorporation into DNA at a time when cell growth was actually inhibited. It is likely that EHNA, being an adenosine analogue, can in high concentrations also decrease pyrimidine nucleotide pools. Thus EHNA at a concentration of 10 FM, when leucine incorporation was inhibited 40%, actually increased thymidine uptake. The incorporation of uridine into RNA, while not specifically measured, would be expected to behave similarly. The addition of adenosine to mitogen-stimulated lymphocytes also had a biphasic effect on tritiated thymidine uptake, with stimulation at low doses and inhibition at millimolar concentrations. The apparent stimulation is consistent with its known effect on reducing the size of pyrimidine nucleotide pools (16) (17) (18) . Here again, leucine incorporation into protein was a more sensitive indicator of adenosine toxicity, with inhibition at concentrations of adenosine as low as 15 AM. The simultaneous presence of EHNA in the culture medium enhanced the inhibition of blastogenesis induced by adenosine. Concentrations as low as 0.1 /M EHNA plus 5 FM adenosine significantly inhibited leucine incorporation (P < 0.05).
The above results do not necessarily indicate that the impairment of lymphocyte proliferation associated with adenosine deaminase inhibition is actually the result of adenosine toxicity, since intracellular adenosine levels were never measured. Indeed, in certain respects the toxicity of EHNA and adenosine differed. For example, uridine was able to reverse partially the inhibitory effects of adenosine, but not EHNA, on thymidine and leucine uptake. Adenosine in high concentrations blocks both de novo purine and pyrimidine biosynthesis by decreasing the formation of phosphoribosyl pyrophosphate. When uridine is in the medium, de novo pyrimidine synthesis is unnecessary for cell survival, and adenosine itself can function as a purine source. EHNA, being nonmetabolizable, cannot function as a source of purines; therefore, uridine should not reverse the inhibitory effects of EHNA. Even a mixture of adenosine and uridine, however, was without effect on EHNA toxicity, indicating that some of the inhibitory effects of EHNA are not related to inhibition of de novo purine and pyrimidine synthesis.
In mouse and human lymphocytes, incubation with pharmacologic concentrations of adenosine (375 AM)
leads to a rise in intracellular cyclic AMP concentrations, an effect that can be potentiated but not simulated by EHNA (8) . This result suggested that some of the immunosuppressive effects of adenosine might be mediated by cyclic AMP, since exogenous cyclic AMP and agents that elevate intracellular cyclic AMP levels can inhibit both lymphocyte transformation and antibody secretion (5, 6, 19, 20) . It must be remembered, however, that intracellular adenosine is converted to adenine nucleotides by adenosine kinase (21) , and might secondarily increase cyclic AMP concentrations simply by enlarging precursor pools. Our approach to this problem was to see if EHNA could potentiate the effects of exogenous cyclic AMP, dibutyryl cyclic AMP, and pharmacologic agents that elevate intracellular cyclic AMP concentrations. The effects of exogenous cyclic AMP upon tritiated thymidine uptake were similar to those of adenosine, with stimulation at low doses, inhibition at millimolar concentrations, potentiation by EHNA, and prevention of toxicity by uridine. On the contrary, dibutyryl cyclic AMP, isoproterenol, norepinephrine, and theophylline failed to stimulate thymidine uptake at any concentration, and their inhibitory effects were unmodified by uridine. The identity of the effects of adenosine and exogenous cyclic AMP and the differing effects of dibutyryl cyclic AMP suggest that the actions of exogenous cyclic AMP are actually mediated by the adenosine to which it is metabolized, as has been previously suggested (6, 22) .
When tritiated thymidine uptake was used as an assay of transformation, EHNA at a concentration of 50 FM (the highest noninhibitory dose) did potentiate the effects of dibutyryl cyclic AMP, norepinephrine, and isoproterenol. It had no effect on theophylline-induced inhibition of thymidine uptake, and indeed, in neuronal cells theophylline has been reported to be an inhibitor of adenosine-mediated elevations of cyclic AMP concentrations (11, 23) . Taken alone, these results suggest that adenosine deaminase inhibition can augment the effects of cyclic AMP. Other experiments, however, failed to support this conclusion. Theophylline was not able to prevent adenosine toxicity. In addition, EHNA at concentrations lower than 50 AM did not enhance the inhibitory effects of dibutyryl cyclic AMP, norepinephrine, or isoproterenol on either thymidine or leucine uptake, at which concentrations synergy with adenosine was readily apparent. The leucine uptake studies further showed that 50 AM EHNA was actually toxic to lymphocytes, but that this effect was masked when thymidine uptake was measured.
To summarize, our results suggest that inhibition of adenosine deaminase with EHNA can depress human lymphocyte blastogenesis. In an experimentally expanding lymphocyte population, even a small decrease in the number of cells dividing, or in the rate of division, could result in severe lymphopenia.
We were unable to determine the exact biochemical mechanisms by which EHNA interfered with lymphocyte proliferation. Inhibition of adenosine deaminase with EHNA did not consistently potentiate the effect of agents that elevate intracellular cyclic AMP concentrations. EHNA did sensitize lymphocytes to the toxic effects of exogenous adenosine and cyclic AMP, presumably by blocking their further metabolism. However, EHNA toxicity, unlike that of adenosine and cyclic AMP, was not reversed by uridine. These results suggest that EHNA-mediated inhibition of lymphocyte transformation does not result from the accumulation of intracellular adenosine or adenine nucleotides. The possibility remains, however, that in patients with adenosine deaminase deficiency, elevated concentrations of circulating adenosine or adenine nucleotides, derived from extracellular, nonlymphoid sources, depress immune development.
Finally, our results also illustrate the difficulties inherent in using thymidine or uridine uptake as indices of lymphocyte blastogenesis. One must remember that any agents, such as adenosine and cyclic AMP, that alter nucleoside transport or intracellular nucleotide pools can either increase or decrease thymidine and uridine uptake independently of any effects on cellular proliferation.
